CHICAGO — In this exclusive video from Digestive Disease Week, Norah Terrault, MD, MPH, discusses the topics reviewed during a press conference involving several experts attending the meeting. Some of the key features of the meeting included new developments for treating hepatitis C, new data emerging on difficult to treat groups such as persons who inject drugs, and the industry’s focus on fatty liver disease.
“While we have many very effective treatments that are currently available [for HCV], there remain some more difficult to cure groups and also a need to try to come up with a simpler, shorter treatment duration,” Terrault said.
On the topic of nonalcoholic fatty liver disease, she commented: “There are state of the art lectures, there’s many clinical symposiums related to the diagnosis, the management and some of the new treatment options that are being looked at — so that I think has a lot of presence here [at DDW].”
: Terrault reports financial relationships with Gilead, AbbVie, BMS, Esai, Dynavax, Infergen, Novartis, Uptodate and Merck.